No Data
No Data
BofA Securities Maintains Ardent Health Partners(ARDT.US) With Hold Rating, Maintains Target Price $17
Ardent Health Partners, Inc.: Balancing Growth Opportunities and Financial Risks With a Hold Rating
Truist Financial Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Announces Target Price $21
Leerink Partners Maintains Ardent Health Partners(ARDT.US) With Buy Rating, Cuts Target Price to $21
Analysts Offer Insights on Healthcare Companies: Denali Therapeutics (DNLI), Ardent Health Partners, Inc. (ARDT) and Doximity (DOCS)
Ardent Health Partners Is Maintained at Outperform by RBC Capital